Biodexa Pharmaceuticals ( (BDRX) ) has provided an update. Spark’s Take on BDRX Stock According to Spark, TipRanks’ AI Analyst, BDRX is a Neutral. Overall score is held down mainly by weak financial performance (no revenue, ongoing losses, and continued cash burn)…
Bausch + Lomb Corporation ( (BLCO) ) just unveiled an announcement. The most recent analyst rating on (BLCO) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock…
An update from Satellos Bioscience ( (TSE:MSCL) ) is now available. The most recent analyst rating on (TSE:MSCL) stock is a Buy with a C$18.00 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see…
Two Massachusetts biotech companies announced plans last week to cut roughly half their workforces as they narrow their focuses to experimental treatments for weight management and diabetes-related vision loss. Burlington-based Fractyl Health announced a 45% workforce reduction, which would eliminate about…
NEWTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid... Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality NEWTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE)…
Pharma sees a potential catch in Washington’s latest effort to curb China’s biotech ambitions Happy Friday, and welcome to Health Brief. Calley Means, a key member of the Make America Healthy Again movement, announced he would be leaving the Trump…
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced plans to develop a rat liver model that will complement…
TD Cowen analyst Tyler Van Buren maintained a Hold rating on Crispr Therapeutics AG today and set a price target of $45.00. According to TipRanks, Van Buren is a top 100 analyst with an average return of 36.1% and a 58.90% success rate. Van…
The Zacks Consensus Estimate for AbbVie’s neuroscience revenues in the third quarter of 2026 is pegged at $3.29 billion. The figure implies year-over-year growth of nearly 16%, with growth expected across most marketed products. Turning to the oral migraine portfolio, the Zacks Consensus…
J.P. Morgan analyst Casey Woodring maintained a Buy rating on Illumina yesterday and set a price target of $320.00. The company’s shares closed yesterday at $262.54. Woodring covers the Healthcare sector, focusing on stocks such as Illumina, Guardant Health, and Natera. According to…
Biotechnology, gene editing, biopharma platforms, and clinical pipelines.
An article joins this feed when it matches these terms. Each one is also a search of its own.